Daily Roundup

PME.ASX VMM.ASX MCE.ASX C79.ASX CTQ.ASX

Pro Medicus Extends Ohio State Contract

Pro Medicus has renewed its partnership with The Ohio State University Wexner Medical Center, inking a five-year deal worth A$16 million. The contract covers Visage 7 Workflow and Visage 7 Cardiology Imaging, with a transaction-based model that could deliver additional upside. This renewal pushes Pro Medicus's total contract renewals for the financial year to A$141 million, underscoring solid client retention across its U.S. operations.

Viridis Locks in Grid Connection for Rare Earth Project

Viridis Mining has signed its first major project delivery contract, securing critical infrastructure for its Colossus Rare Earth Project in Brazil. The company has partnered with municipal electricity distributor DME to build a 3.2-kilometer, 138kV transmission line connecting the project to the Brazilian grid. The fixed-price package comes in at approximately BRL3.97 million (around US$0.8 million), offering cost certainty without exposure to construction escalation. With grid capacity reserved from December 2027, the project is on track to support first production in the first half of 2028. The infrastructure is being designed with capacity for up to 90MVA, leaving room for future expansion as the project scales.

Matrix Composites Shareholders Prepare for Vote

Matrix Composites & Engineering has released its Scheme Booklet for the proposed acquisition by Advanced Innergy Solutions Australia, a subsidiary of Advanced Innergy Holdings. ASIC has now registered the booklet, clearing the way for shareholders to review the details ahead of the Scheme Meeting on July 6, 2026. The Matrix board unanimously recommends voting in favor of the deal, and an independent expert has concluded the scheme is fair and reasonable.

Chrysos Secures $200M Facility to Fuel PhotonAssay Expansion

Chrysos Corporation has refinanced its corporate facilities with a new AUD$200 million syndicated debt facility, courtesy of ANZ, NAB, and Export Finance Australia. The three-year facility comes with better pricing, lower commitment fees, and improved covenants compared to its previous asset-based structure. The company is ramping up production of its PhotonAssay units to 18 per year, with a forward order book already extending to 22 units. Strong market demand is evident, with 23 new lease agreements signed year-to-date and the company processing over one million samples for three consecutive months as the gold market remains buoyant.

Careteq Simplifies Capital Structure with Convertible Note Conversion

Strategic investor Antanas Guoga has converted 355,678 convertible notes into 35.6 million ordinary shares at $0.01 per share, simplifying Careteq's balance sheet. The move reflects Guoga's confidence in the healthtech company's direction and removes convertible notes from the capital structure entirely. With no drawn debt facilities and a cleaner cap table, Careteq can now focus on scaling its HMR Referrals platform and broader AI-enabled healthtech offerings.